Both groups used RNA aptamers targeting prostate-specific membrane antigen (PSMA) to deliver siRNAs to prostate cancer cells specifically (Kruspe and Giangrande, 2017; Soldevilla et al., 2018). This evidence concerns the gene FOLH1 and prostate cancer.